Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function – A multicentre, double-blind, randomized, placebo-controlled trial – SERVE

SERVE was a double-blind, randomized, placebo-controlled, multicenter superiority trial (NCT03049540) conducted in Switzerland. The study enrolled 100 adults with a systemic right ventricle (sRV), comparing tadalafil 20 mg once daily versus placebo over a 3-year period. More information: www.sacher-registry.com/serve

The primary endpoint was the change in right ventricular end-systolic volume (RVESV); secondary endpoints included changes in right ventricular ejection fraction, NT-proBNP levels, and exercise capacity.

I was involved as a Co-Investigator at the Basel and Bern center, contributing to patient enrollment, follow-up, and data analysis.

Related peer-reviewed publications are available at:

👉 https://www.sacher-registry.com/serve/publications/accepted-manuscripts/